Furan π Bridge Strengthens Conformation Locking in Asymmetric D‐A‐π‐D NIR‐II AIEgens for High‐Efficiency Photothermal/NO Synergistic Therapy
Advanced Science · 15.11.2026
DOI: 10.1002/advs.78807 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.11.2026. Verfasst von Ji Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, China. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation Committee of China, Fundamental Research Funds for the Central Universities, High-level Talent Research Facilities Funding of Nantong University.
Abstract (Originalsprache)
Methicillin‐resistant Staphylococcus aureus (MRSA) pneumonia represents a critical threat owing to its high mortality and antibiotic resistance. Near‐infrared II (NIR‐II) fluorescent photothermal therapy (PTT) enables deep‐tissue heating but risks incomplete bacterial clearance and thermal damage. Symmetric donor‐acceptor‐donor (D‐A‐D) NIR‐II molecules often suffer from high molecular weights, low fluorescence, and suboptimal photothermal conversion. Herein, we report asymmetric D‐A‐π‐D NIR‐II aggregation‐induced emission luminogens (AIEgens) featuring a benzothiopyrylium acceptor, triphenylamine donors, and furan or thiophene as π‐bridge. Furan strengthens non‐covalent conformation locking while weakening intermolecular π–π stacking, thereby enhancing both fluorescence and photothermal performance. AIEgen 4fop achieves an optimal photothermal conversion efficiency of 84.3% and a NIR‐II photoluminescence quantum yield of 2.31% in toluene. To boost antibacterial activity, 4fop was co‐encapsulated with the thermally responsive NO donor BNN6 into Pluronic F‐127 nanoparticles. In a murine pneumonia model, this nanoplatform substantially reduces bacterial burden, suppresses inflammation through TNF pathway modulation, and promotes lung repair. This work establishes a rational D‐A‐π‐D design strategy and an integrated nanoplatform for the precise treatment of deep‐seated drug‐resistant infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, China.
- Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China.
- State Key Laboratory of Materials Low-Carbon Recycling, Department of Chemistry, College of Chemistry and Life Science, Beijing University of Technology, Beijing, China.
ORCID-Profile: Fengyan Song, Qifeng Zhong, Zhenwei Yuan
Förderung
- Natural Science Foundation Committee of China
- Fundamental Research Funds for the Central Universities
- High-level Talent Research Facilities Funding of Nantong University
- the Excellent Young Foundation of Jiangsu Province
Zitieren
APA
Liu, J., Wang, K., Li, J., Liu, X., Lin, J., Wang, S., Wang, P., Chu, A., Xiong, M., Zhou, Y., Liu, D., Yang, C., Song, F., Zhong, Q., & Yuan, Z. (2026). Furan π Bridge Strengthens Conformation Locking in Asymmetric D‐A‐π‐D NIR‐II AIEgens for High‐Efficiency Photothermal/NO Synergistic Therapy. Advanced Science. https://doi.org/10.1002/advs.78807
Vancouver
Liu J, Wang K, Li J, Liu X, Lin J, Wang S, et al. Furan π Bridge Strengthens Conformation Locking in Asymmetric D‐A‐π‐D NIR‐II AIEgens for High‐Efficiency Photothermal/NO Synergistic Therapy. Advanced Science. 2026. doi:10.1002/advs.78807
BibTeX
@article{Liu2026,
author = {Liu, Ji and Wang, Kaizhen and Li, Jiaqiao and Liu, Xiao and Lin, Jingjing and Wang, Shiya and Wang, Pengbo and Chu, Anran and Xiong, Minxuan and Zhou, Yiyang and Liu, Dongwei and Yang, Chenyi and Song, Fengyan and Zhong, Qifeng and Yuan, Zhenwei},
title = {Furan π Bridge Strengthens Conformation Locking in Asymmetric D‐A‐π‐D NIR‐II AIEgens for High‐Efficiency Photothermal/NO Synergistic Therapy},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78807}
}
EUVIMED